Trial · NCT00886626
GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children
NCT00886626, Phase 2, Completed, University of Minnesota; results first posted 2012-08-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children. Trials, record NCT00886626. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00886626
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children
- NCT number
- NCT00886626
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 12 participants, actual
- Lead sponsor
- University of Minnesota
- Conditions
- Obesity, Morbid
- Interventions
- Exenatide
- First posted
- 2009-04-23
- Last updated
- 2012-10-29
- Results first posted
- 2012-08-17
- Limitations and caveats
- Small sample size; un-blinded; crossover study design
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Body Mass Index (BMI) | 3-month | Change in body mass index (BMI) over three months |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Body Mass Index (BMI) | 3-month | Data from all participants who completed the trial were analyzed. | change in kg/m^2 | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Body Mass Index (BMI) | Exenatide | -0.9 | Standard Deviation 1.2 | change in kg/m^2 | |
| Change in Body Mass Index (BMI) | Control | 0.84 | Standard Deviation 1.3 | change in kg/m^2 |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Period 1 (90 Days) | STARTED | Exenatide Then Control | 6 | |
| Period 1 (90 Days) | STARTED | Control Then Exenatide | 6 | |
| Period 1 (90 Days) | COMPLETED | Exenatide Then Control | 5 | |
| Period 1 (90 Days) | COMPLETED | Control Then Exenatide | 6 | |
| Period 1 (90 Days) | NOT COMPLETED | Exenatide Then Control | 1 | |
| Period 1 (90 Days) | NOT COMPLETED | Control Then Exenatide | 0 | |
| Period 2 (90 Days) | STARTED | Exenatide Then Control | 5 | |
| Period 2 (90 Days) | STARTED | Control Then Exenatide | 6 | |
| Period 2 (90 Days) | COMPLETED | Exenatide Then Control | 5 | |
| Period 2 (90 Days) | COMPLETED | Control Then Exenatide | 6 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Exenatide | 4 | 11 | 4 |
| other | Nausea | Gastrointestinal disorders | Control | 0 | 11 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Exenatide | ||
| Total, all-cause mortality | Control | ||
| Total, other adverse events | Exenatide | 4 | 11 |
| Total, other adverse events | Control | 0 | 11 |
| Total, serious adverse events | Exenatide | 0 | 11 |
| Total, serious adverse events | Control | 0 | 11 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 22076596 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Exenatide vs Control: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00886626
GET https://conductscience.org/api/trials/v1/NCT00886626/registered